Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A phase II trial of CI-921 in advanced malignancies
Investigational New Drugs, Volume 10, No. 4, Year 1992
Notification
URL copied to clipboard!
Description
CI-921, (9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate (1:1)), an anilinoacridine derivative with activity in experimental solid tumors was studied in a multicenter phase II trial in patients with solid tumors. Eligible tumor types included cancers of the breast, stomach, pancreas, nonsmall cell lung, small cell lung, colon, head and neck area, and melanoma. Prestudy requirements included an ECOG performance status of ≤ 2, no CNS metastases, and measurable disease. CI-921 was administered intravenously over 1-2 hours on days 1,8, and 15 of a 35-day course at an initial dose of 270 mg/M2, with modification in subsequent courses based upon tolerance. Principal toxicities included leukopenia, marked phlebitis, and mild nausea and vomiting. One hundred fifty patients were entered of whom 132 were evaluable for response. There was one complete and one partial response among 19 patients with breast cancer, and two partial responses, one each among 14 head and neck and 36 nonsmall cell lung cancer patients. © 1992 Kluwer Academic Publishers.
Authors & Co-Authors
Sklarin, Nancy T.
United States, New York
Montefiore Medical Center
Wiernik, Peter H.
United States, New York
Albert Einstein Cancer Center of the Albert Einstein College of Medicine of Yeshiva University
Grove, William R.
United States, New York
Pfizer Inc.
Benson, Laura
United States, New York
Montefiore Medical Center
Mittelman, Abraham
United States, Valhalla
New York Medical Center
Maroun, Jean A.
Canada, Ottawa
The Ottawa Hospital Cancer Centre
Stewart, James A.
United States, Burlington
University of Vermont Larner College of Medicine
Robert, Francisco
United States, San Juan
San Juan Municipio
Doroshow, James H.
United States, Duarte
City of Hope National Med Center
Rosen, Peter J.
United States, Los Angeles
University of Southern California
Jolivet, Jacques
Canada, Montreal
Hôpital Notre-dame
Ruckdeschel, John C.
United States, Albany
Albany Medical College
Robert, Nicholas J.
United States, Boston
Tufts Medical Center
Vélez-Garciá, Enríque O.
Puerto Rico, San Juan
Universidad de Puerto Rico
Bergsagel, Daniel E.
Canada, Toronto
Princess Margaret Cancer Centre
Panasci, Lawrence C.
Canada, Montreal
Sir Mortimer B. Davis Jewish General Hospital
van der Merwe, Aletta M.
South Africa, Tygerberg
Tygerberg Hospital
Longueville, Jacques J.
Belgium, Brussels
Cliniques Universitaires Saint-luc
Leiby, Jane
United States, Columbus
The Ohio State University Wexner Medical Center
Kowal, Charles D.
United States, Columbus
The Ohio State University Wexner Medical Center
Statistics
Citations: 20
Authors: 20
Affiliations: 18
Identifiers
Doi:
10.1007/BF00944186
ISSN:
01676997
e-ISSN:
15730646
Research Areas
Cancer